vs
Apellis Pharmaceuticals, Inc.（APLS）与TREX CO INC（TREX）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是TREX CO INC的1.2倍（$199.9M vs $161.1M），TREX CO INC净利率更高（1.4% vs -29.5%，领先30.9%），TREX CO INC同比增速更快（-3.9% vs -5.9%），TREX CO INC自由现金流更多（$22.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -34.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Trex公司是木塑复合替代板材、住宅护栏及其他户外用品的制造商，产品采用回收材料生产，总部位于美国弗吉尼亚州温彻斯特，是户外家居建材领域的知名企业，主打环保耐用的户外搭建解决方案。
APLS vs TREX — 直观对比
营收规模更大
APLS
是对方的1.2倍
$161.1M
营收增速更快
TREX
高出2.1%
-5.9%
净利率更高
TREX
高出30.9%
-29.5%
自由现金流更多
TREX
多$36.4M
$-14.3M
两年增速更快
APLS
近两年复合增速
-34.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $161.1M |
| 净利润 | $-59.0M | $2.3M |
| 毛利率 | — | 30.2% |
| 营业利润率 | -25.6% | 2.2% |
| 净利率 | -29.5% | 1.4% |
| 营收同比 | -5.9% | -3.9% |
| 净利润同比 | -62.2% | -76.4% |
| 每股收益（稀释后） | $-0.40 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTREX
| Q4 25 | $199.9M | $161.1M | ||
| Q3 25 | $458.6M | $285.3M | ||
| Q2 25 | $178.5M | $387.8M | ||
| Q1 25 | $166.8M | $340.0M | ||
| Q4 24 | $212.5M | $167.6M | ||
| Q3 24 | $196.8M | $233.7M | ||
| Q2 24 | $199.7M | $376.5M | ||
| Q1 24 | $172.3M | $373.6M |
净利润APLSTREX
| Q4 25 | $-59.0M | $2.3M | ||
| Q3 25 | $215.7M | $51.8M | ||
| Q2 25 | $-42.2M | $75.9M | ||
| Q1 25 | $-92.2M | $60.4M | ||
| Q4 24 | $-36.4M | $9.8M | ||
| Q3 24 | $-57.4M | $40.6M | ||
| Q2 24 | $-37.7M | $87.0M | ||
| Q1 24 | $-66.4M | $89.1M |
毛利率APLSTREX
| Q4 25 | — | 30.2% | ||
| Q3 25 | — | 40.5% | ||
| Q2 25 | — | 40.8% | ||
| Q1 25 | — | 40.5% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 39.9% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 45.4% |
营业利润率APLSTREX
| Q4 25 | -25.6% | 2.2% | ||
| Q3 25 | 48.7% | 24.7% | ||
| Q2 25 | -18.6% | 26.4% | ||
| Q1 25 | -50.0% | 24.0% | ||
| Q4 24 | -12.3% | 9.2% | ||
| Q3 24 | -24.0% | 23.2% | ||
| Q2 24 | -14.7% | 31.1% | ||
| Q1 24 | -36.0% | 31.9% |
净利率APLSTREX
| Q4 25 | -29.5% | 1.4% | ||
| Q3 25 | 47.0% | 18.1% | ||
| Q2 25 | -23.6% | 19.6% | ||
| Q1 25 | -55.3% | 17.8% | ||
| Q4 24 | -17.1% | 5.8% | ||
| Q3 24 | -29.2% | 17.4% | ||
| Q2 24 | -18.9% | 23.1% | ||
| Q1 24 | -38.5% | 23.8% |
每股收益（稀释后）APLSTREX
| Q4 25 | $-0.40 | $0.03 | ||
| Q3 25 | $1.67 | $0.48 | ||
| Q2 25 | $-0.33 | $0.71 | ||
| Q1 25 | $-0.74 | $0.56 | ||
| Q4 24 | $-0.30 | $0.10 | ||
| Q3 24 | $-0.46 | $0.37 | ||
| Q2 24 | $-0.30 | $0.80 | ||
| Q1 24 | $-0.54 | $0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $3.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.0B |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSTREX
| Q4 25 | $466.2M | $3.8M | ||
| Q3 25 | $479.2M | $11.4M | ||
| Q2 25 | $370.0M | $5.5M | ||
| Q1 25 | $358.4M | $5.0M | ||
| Q4 24 | $411.3M | $1.3M | ||
| Q3 24 | $396.9M | $12.8M | ||
| Q2 24 | $360.1M | $1.2M | ||
| Q1 24 | $325.9M | $3.1M |
总债务APLSTREX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSTREX
| Q4 25 | $370.1M | $1.0B | ||
| Q3 25 | $401.2M | $1.0B | ||
| Q2 25 | $156.3M | $989.3M | ||
| Q1 25 | $164.2M | $910.1M | ||
| Q4 24 | $228.5M | $850.1M | ||
| Q3 24 | $237.1M | $887.9M | ||
| Q2 24 | $264.3M | $894.9M | ||
| Q1 24 | $266.7M | $804.1M |
总资产APLSTREX
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $821.4M | $1.5B | ||
| Q1 25 | $807.3M | $1.6B | ||
| Q4 24 | $885.1M | $1.3B | ||
| Q3 24 | $901.9M | $1.3B | ||
| Q2 24 | $904.5M | $1.3B | ||
| Q1 24 | $831.9M | $1.3B |
负债/权益比APLSTREX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $65.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $22.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 13.7% |
| 资本支出强度资本支出/营收 | 0.1% | 26.9% |
| 现金转化率经营现金流/净利润 | — | 28.45× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $134.5M |
8季度趋势，按日历期对齐
经营现金流APLSTREX
| Q4 25 | $-14.2M | $65.5M | ||
| Q3 25 | $108.5M | $196.9M | ||
| Q2 25 | $4.4M | $249.8M | ||
| Q1 25 | $-53.4M | $-154.0M | ||
| Q4 24 | $19.4M | $-8.5M | ||
| Q3 24 | $34.1M | $132.8M | ||
| Q2 24 | $-8.3M | $193.7M | ||
| Q1 24 | $-133.0M | $-174.0M |
自由现金流APLSTREX
| Q4 25 | $-14.3M | $22.1M | ||
| Q3 25 | $108.3M | $142.9M | ||
| Q2 25 | $4.4M | $203.0M | ||
| Q1 25 | $-53.4M | $-233.5M | ||
| Q4 24 | $19.3M | $-89.3M | ||
| Q3 24 | — | $54.5M | ||
| Q2 24 | $-8.4M | $158.2M | ||
| Q1 24 | $-133.3M | $-211.8M |
自由现金流率APLSTREX
| Q4 25 | -7.1% | 13.7% | ||
| Q3 25 | 23.6% | 50.1% | ||
| Q2 25 | 2.5% | 52.3% | ||
| Q1 25 | -32.0% | -68.7% | ||
| Q4 24 | 9.1% | -53.3% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | -4.2% | 42.0% | ||
| Q1 24 | -77.3% | -56.7% |
资本支出强度APLSTREX
| Q4 25 | 0.1% | 26.9% | ||
| Q3 25 | 0.0% | 18.9% | ||
| Q2 25 | 0.0% | 12.1% | ||
| Q1 25 | 0.0% | 23.4% | ||
| Q4 24 | 0.0% | 48.2% | ||
| Q3 24 | 0.0% | 33.5% | ||
| Q2 24 | 0.0% | 9.4% | ||
| Q1 24 | 0.2% | 10.1% |
现金转化率APLSTREX
| Q4 25 | — | 28.45× | ||
| Q3 25 | 0.50× | 3.80× | ||
| Q2 25 | — | 3.29× | ||
| Q1 25 | — | -2.55× | ||
| Q4 24 | — | -0.87× | ||
| Q3 24 | — | 3.27× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | — | -1.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TREX
暂无分部数据
